Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease - PubMed (original) (raw)
Comparative Study
doi: 10.1053/bbmt.2003.50006.
Affiliations
- PMID: 12652467
- DOI: 10.1053/bbmt.2003.50006
Free article
Comparative Study
Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease
Geoffrey W Chan et al. Biol Blood Marrow Transplant. 2003 Mar.
Free article
Abstract
Graft-versus-host disease (GVHD) causes significant morbidity and mortality in patients undergoing allogeneic bone marrow transplantation following either a conventional or reduced-intensity preparative regimen. In a murine model, inactivation of host dendritic cells (DCs) was associated with a significant reduction in acute GVHD, suggesting that host DCs may play an important role in the pathogenesis of acute GVHD. The role of host DCs in the development of GVHD following allogeneic stem cell transplantation in humans, however, is unclear. We examined DC chimerism in patients with various hematologic malignancies who underwent a reduced-intensity preparative regimen of extracorporeal photophoresis, pentostatin, and reduced-dose total body irradiation (n = 21) or a conventional preparative regimen of cyclophosphamide and total body irradiation (n = 3). Full donor hematopoietic reconstitution was demonstrated in 19 of 21 patients who underwent a reduced-intensity preparative regimen and in all patients who underwent a conventional preparative regimen. Grade 0 to I acute GVHD and limited or no chronic GVHD were observed in 18 patients who underwent a reduced-intensity regimen and 1 patient who underwent a conventional regimen who achieved full donor DC chimerism at day +100 posttransplantation. In contrast, grade II to IV acute GVHD and extensive chronic GVHD were observed in the 2 patients who underwent a conventional regimen and the 1 patient who underwent a reduced-intensity regimen who had host rather than donor DC chimerism. The persistence of host DCs at day +100 posttransplantation is correlated with the development of severe acute and chronic GVHD (P =.001). Host DCs may represent a therapeutic target for reducing GVHD in allogeneic bone marrow transplants.
Copyright 2003 American Society for Blood and Marrow Transplantation
Similar articles
- Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, Landonio G, Locatelli F, Siena S, Della Cuna GR. Pedrazzoli P, et al. Cancer. 2002 May 1;94(9):2409-15. doi: 10.1002/cncr.10491. Cancer. 2002. PMID: 12015766 - Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution.
Nakai K, Mineishi S, Kami M, Saito T, Hori A, Kojima R, Imataki O, Hamaki T, Yoshihara S, Ohnishi M, Kim SW, Ando T, Fumitoh A, Kanda Y, Makimoto A, Tanosaki R, Kanai S, Heike Y, Ohnishi T, Kawano Y, Wakasugi H, Takaue Y. Nakai K, et al. Transplantation. 2003 Jun 27;75(12):2135-43. doi: 10.1097/01.TP.0000066453.32263.F7. Transplantation. 2003. PMID: 12829926 - The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM. Foss FM. Semin Hematol. 2006 Apr;43(2 Suppl 2):S35-43. doi: 10.1053/j.seminhematol.2005.12.007. Semin Hematol. 2006. PMID: 16549113 Review. - Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Levine JE, Uberti JP, Ayash L, Reynolds C, Ferrara JL, Silver SM, Braun T, Yanik G, Hutchinson R, Ratanatharathorn V. Levine JE, et al. Biol Blood Marrow Transplant. 2003 Mar;9(3):189-97. doi: 10.1053/bbmt.2003.50012. Biol Blood Marrow Transplant. 2003. PMID: 12652470 Clinical Trial.
Cited by
- Allogeneic stem cell transplantation in the treatment of acute myeloid leukemia: An overview of obstacles and opportunities.
Chen YF, Li J, Xu LL, Găman MA, Zou ZY. Chen YF, et al. World J Clin Cases. 2023 Jan 16;11(2):268-291. doi: 10.12998/wjcc.v11.i2.268. World J Clin Cases. 2023. PMID: 36686358 Free PMC article. Review. - A unique immune signature in blood separates therapy-refractory from therapy-responsive acute graft-versus-host disease.
van Halteren AGS, Suwandi JS, Tuit S, Borst J, Laban S, Tsonaka R, Struijk A, Wiekmeijer AS, van Pel M, Roep BO, Zwaginga JJ, Lankester AC, Schepers K, van Tol MJD, Fibbe WE. van Halteren AGS, et al. Blood. 2023 Mar 16;141(11):1277-1292. doi: 10.1182/blood.2022015734. Blood. 2023. PMID: 36044666 Free PMC article. - Innate Immune Determinants of Graft-Versus-Host Disease and Bidirectional Immune Tolerance in Allogeneic Transplantation.
Hamers AAJ, Joshi SK, Pillai AB. Hamers AAJ, et al. OBM Transplant. 2019;3(1):10.21926/obm.transplant.1901044. doi: 10.21926/obm.transplant.1901044. Epub 2019 Jan 31. OBM Transplant. 2019. PMID: 33511333 Free PMC article. - Restoring T Cell Homeostasis After Allogeneic Stem Cell Transplantation; Principal Limitations and Future Challenges.
Moutuou MM, Pagé G, Zaid I, Lesage S, Guimond M. Moutuou MM, et al. Front Immunol. 2018 Jun 18;9:1237. doi: 10.3389/fimmu.2018.01237. eCollection 2018. Front Immunol. 2018. PMID: 29967605 Free PMC article. Review. - The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.
Ren HG, Adom D, Paczesny S. Ren HG, et al. Expert Rev Clin Immunol. 2018 May;14(5):389-404. doi: 10.1080/1744666X.2018.1463159. Epub 2018 Apr 19. Expert Rev Clin Immunol. 2018. PMID: 29629613 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical